Shaily Engineering launches semaglutide pens in Canada
The company enters regulated drug delivery markets with two commercial launches and tentative US FDA approval, while healthcare revenue jumps 139%.
What's new
- Commercial launch of pen injectors for generic semaglutide in Canada via two customers.
- Tentative US FDA approval secured for the company's drug delivery devices.
- New supply agreement signed with a Korean firm for semiconductor trays.
Why this matters
Shaily is successfully pivoting from general plastics into high-margin regulated healthcare and semiconductor segments. The 139% surge in healthcare revenue confirms that these specialized bets are already scaling rapidly.
What we're watching
- Production line ramp-up speeds to meet the 36 million unit target.
- Conversion of tentative US FDA approval into full commercial authorization.
- Margin impact from the new semiconductor tray supply contract.
The full read
Shaily Engineering Plastics is moving into regulated drug delivery markets. The company confirmed the commercial launch of its pen injectors for generic semaglutide in Canada, supported by two customers. It also received tentative US FDA approval, a key step for its healthcare expansion. Financials reflect this shift: healthcare revenue surged 139% to ₹393 crore for the year, helping drive total consolidated revenue up 26% to ₹991 crore and net profit up 83% to ₹170 crore. Beyond healthcare, the company is diversifying into electronics and semiconductors, having started supplies to a consumer electronics client and signed a deal for semiconductor trays with a Korean partner. Management is now targeting 36 million units for semaglutide pens this year. Success hinges on how quickly they can bring new production lines online to meet that volume.
Questions answered
- What is the status of the semaglutide pen injector program?
- The pens are now commercially launched in Canada through two customers. The company also holds tentative US FDA approval for the devices.
- How did the healthcare segment perform in the full year?
- Healthcare revenue grew 139% to ₹393 crore. This growth significantly outpaced the company's overall consolidated revenue growth of 26%.
- What are the new business wins outside of healthcare?
- Shaily began commercial supplies to a consumer electronics customer and signed a supply agreement with a Korean company for semiconductor trays.
- What is the volume guidance for the current financial year?
- Management expects to supply 36 million units of semaglutide pens. This target depends on the successful ramp-up of new production lines.